Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE

Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer’ (P008) was presented at the 17th St. Gallen Breast Cancer Conference 2021. 

Questions

1. Why have patient-reported outcomes been neglected in clinical studies until recently, and why are they so important? (00:11)
2. Could you give us a brief overview of the aims and design of the MonarchE study? (00:42)
3. What patient-recorded outcomes are being evaluated and what have been the preliminary findings? (02:34)
4. What are the significance of these findings for the management of patients with HER2- breast cancer? (04:59)

Disclosures: Dr Sara Tolaney has no financial or non-financial relationships or activities to declare in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 17th St. Gallen Breast Cancer Conference 2021.

References

• Tolaney S, Blancas I, Im Y-H, et al. Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer. The Breast. 2021;56(Suppl. 1):S20–1.
• ClinicalTrials.gov. Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE). ClinicalTrials.gov Identifier: NCT03155997. Available at: https://clinicaltrials.gov/ct2/show/NCT03155997 (accessed 31 March 2021).

HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; PRO = patient-reported outcomes.